Valuation: Larimar Therapeutics, Inc.

Market Cap 383M 335M 310M 284M 538M 36.91B 547M 3.69B 1.45B 18.03B 1.44B 1.41B 62.23B P/E 2026 *
-2.27x
P/E 2027 * -2.95x
Enterprise Value 207M 181M 167M 153M 290M 19.92B 295M 1.99B 783M 9.73B 776M 759M 33.58B EV / Sales 2026 *
-
EV / Sales 2027 * 3.07x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day-3.67%
1 week-11.14%
Current month+20.33%
1 month+7.94%
3 months-22.25%
6 months+17.25%
Current year-3.67%
1 week 3.54
Extreme 3.535
4.22
1 month 2.92
Extreme 2.92
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer - 2018-04-30
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Buy

Director

50,000 0.0584%
5/19/26 Free

Director

55,150 0.0644%
5/19/26
Deerfield Management Co. LP
FreeCompany 55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-11.14%+14.69%+14.33% 383M
-3.42%+4.90%+61.15%+87.70% 55.98B
-0.05%-5.85%+54.36%+124.61% 53.69B
-2.14%-9.13%+2.74%+421.65% 23.29B
-0.47%-1.53%-18.61%-15.41% 23.15B
-5.29%-1.90%+31.59%-8.84% 20.58B
-0.29%-2.05%+34.41%-27.98% 17.76B
-4.55%-1.95%+192.65%+349.58% 16.09B
-6.33%-5.29%+27.26%+648.58% 15.93B
+0.23%-2.49%+24.26%+187.16% 14B
Average -2.60%-1.50%+42.45%+178.14% 24.09B
Weighted average by Cap. -2.25%-0.90%+46.15%+161.79%

Financials

2026 *2027 *
Net sales - 57.06M 49.88M 46.13M 42.33M 80.11M 5.5B 81.51M 550M 216M 2.69B 214M 210M 9.27B
Net income -157M -138M -127M -117M -221M -15.17B -225M -1.52B -596M -7.41B -591M -578M -25.58B -157M -137M -127M -116M -220M -15.09B -224M -1.51B -593M -7.37B -588M -575M -25.45B
Net Debt -176M -154M -143M -131M -248M -17B -252M -1.7B -668M -8.3B -662M -648M -28.66B -208M -182M -168M -154M -292M -20.03B -297M -2B -787M -9.78B -781M -764M -33.77B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-16 US$3.670 -3.67% 1,336,205
26-07-15 US$3.810 +2.42% 1,269,914
26-07-14 US$3.720 -0.13% 1,842,147
26-07-13 US$3.725 -12.97% 2,297,804
26-07-10 US$4.280 +3.63% 3,445,587
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.670USD
Average target price
14.40USD
Spread / Average Target
+292.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock